An additional study showed a prognostic significance between CD68+ and CD163+ in head and neck squamous cell carcinoma, and they found that CD68+ has no prognosis in patients, whereas CD163+ predicts poor prognosis [28]. This evidence concerns the gene CD68 and head and neck squamous cell carcinoma.